Atlantic Union Bankshares Corporation (AUB) News

PRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the Horizon

NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) --  PRISM MarketView presents an in-depth interview with Dr...

SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference

SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference PR...

Soligenix Encourages Stockholders to Vote Prior to Annual Meeting

Soligenix Encourages Stockholders to Vote Prior to Annual Meeting PR Newswire PRINCETON, N.J., May 20, 2024...

Form 8-K - Current report

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice

Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results

Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results PR Newswire PRINCETON...

Soligenix to Present at Upcoming Conferences

Soligenix to Present at Upcoming Conferences PR Newswire PRINCETON, N.J., May 6, 2024 PRINCETON, N.J., May 6...

Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa

Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South...

Soligenix Announces Pricing of $4.75 Million Public Offering

Soligenix Announces Pricing of $4.75 Million Public Offering PR Newswire PRINCETON, N.J., April 18, 2024 PRINCETON, N.J., April 18, 2024...

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection PR...

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection PR...